| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| He Wei-Wu | 45% | +30% | $14,524,156 | +$5,200,000 | 13,965,535 | +56% | WEI-WU HE, Ph.D. | 09 Feb 2026 |
| Panacea Innovation Ltd | 22% | +13% | $4,698,042 | +$999,856 | 4,651,527 | +27% | James Huang | 16 Dec 2025 |
| Chen Zhenfeng M | 11% | $4,150,370 | 2,255,636 | Chen Zhenfeng | 30 Sep 2025 | |||
| Huang James | 14% | $3,177,509 | 2,161,571 | James Huang | 30 Jun 2025 | |||
| SPARKLE BYTE LTD | 5% | $775,088 | 1,019,852 | SPARKLE BYTE LTD | 30 Sep 2025 | |||
| Ho Chi Sing | 4.8% | -27% | $754,405 | 992,638 | 0% | Zhou Quan | 30 Sep 2025 |
As of 30 Sep 2025, 21 institutional investors reported holding 2,606,843 shares of CASI Pharmaceuticals, Inc. - Ordinary Shares, par value $0.0001 (CASI). This represents 8.5% of the company’s total 30,761,090 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 63,747 | $54,184 | -$186,551 | $0.85 | 10 |
| 2025 Q3 | 2,606,843 | $4,327,257 | +$649,422 | $1.66 | 21 |
| 2025 Q2 | 2,245,168 | $2,648,852 | -$589,075 | $1.18 | 23 |
| 2025 Q1 | 2,744,278 | $5,927,688 | +$186,001 | $2.16 | 22 |
| 2024 Q4 | 2,658,168 | $7,523,090 | -$53,802 | $2.83 | 22 |
| 2024 Q3 | 1,322,529 | $8,138,853 | +$5,984,886 | $6.16 | 20 |
| 2024 Q2 | 352,170 | $1,936,256 | +$552,357 | $5.50 | 23 |
| 2024 Q1 | 252,002 | $909,576 | -$261,433 | $3.61 | 20 |
| 2023 Q4 | 275,894 | $1,981,066 | -$338,820 | $7.16 | 17 |
| 2023 Q3 | 344,608 | $882,628 | -$268,771 | $2.56 | 18 |
| 2023 Q2 | 449,838 | $1,124,376 | -$1,180,810 | $2.50 | 18 |
| 2023 Q1 | 929,752 | $2,152,582 | +$2,152,350 | $2.32 | 19 |
| 2022 Q4 | 100 | $179 | +$179 | $1.79 | 1 |